Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01992874 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability of Pimasertib in Cancer Patients
A Phase 1 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01992874 is a Phase 1 study that has completed, run by EMD Serono. The registered enrollment target is 38 participants.
The verdict
NCT01992874, a Phase 1 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a Phase 1, multi-center, open-label, single-dose, 2 period, 2 sequence cross-over trial to investigate the relative bioavailability of 2 solid oral pimasertib formulations in cancer subjects (Part A), followed by open-label pimasertib administration (Part B and trial extension phase).
Interventions
- DRUG Pimasertib Capsule (Part A)
- DRUG Pimasertib Tablet (Part A)
- DRUG Pimasertib Capsule (Part B and trial extension phase)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2013-11-30 |
| Est. Completion | 2015-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01992874
The ClinicalTrials.gov registry entry for NCT01992874 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pimasertib Capsule (Part A) is the first listed.
NCT01992874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01992874 about?
NCT01992874 is a clinical study titled "Relative Bioavailability of Pimasertib in Cancer Patients". This is a Phase 1, multi-center, open-label, single-dose, 2 period, 2 sequence cross-over trial to investigate the relative bioavailability of 2 solid oral pimasertib formulations in cancer subjects (Part A), followed by open-label pimasertib administration (Part B and trial extension phase).
What is the current status of trial NCT01992874?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2013-11-30. Estimated completion is 2015-02-28.
What interventions are being tested in trial NCT01992874?
The interventions under investigation include: Pimasertib Capsule (Part A) (DRUG), Pimasertib Tablet (Part A) (DRUG), Pimasertib Capsule (Part B and trial extension phase) (DRUG).
Who is sponsoring clinical trial NCT01992874?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.